Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077495 | 0.88 | ADRB2 (0.52) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL13040085 | 0.88 | ADRB2 (0.43) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL13077531 | 0.86 | ADRB2 (0.43) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL13077521 | 0.86 | ADRB2 (0.58) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL13077004 | 0.80 | ADRA2A (0.43) | ADRA1ATSHR | |
| SCHEMBL13077514 | 0.77 | ADRB2 (0.46) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL13040078 | 0.76 | ADRB2 (0.41) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL13077540 | 0.76 | ADRB2 (0.58) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL13040080 | 0.73 | ADRB2 (0.56) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL13077526 | 0.70 | ADRB2 (0.57) | ADRB2ADRB1ADRA1ARECQLLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825263-B2 | Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive | NICOX S.A. (FR) | 2010-11-02 | — | — | US | disclosed |